Federation of American Hospitals Taps New Government Relations Head

Why It Matters

With federal cuts threatening hospital revenue streams, FAH’s strengthened lobbying could shape policy outcomes that protect profitability and patient access. Schwartz’s pharma‑government background positions the trade group to navigate complex regulatory reforms.

Key Takeaways

• Elizabeth Schwartz moves from Merck to lead FAH government relations.
• FAH represents about 1,000 for‑profit community hospitals nationwide.
• Lobbying spend hit $3.6 million in 2025, highest since 2019.
• Federal Medicaid cuts and expired ACA subsidies pressure hospital finances.
• Schwartz’s policy and political expertise aims to safeguard hospital revenue.

Pulse Analysis

The Federation of American Hospitals, the trade association that voices the interests of roughly 1,000 for‑profit community hospitals, announced on May 8 that Elizabeth Schwartz will assume the role of senior vice president and head of government relations. Schwartz arrives from Merck, where she spent nearly a decade steering U.S. policy and government‑relations initiatives for the pharmaceutical giant. Her appointment comes at a time when the association has intensified its lobbying efforts, spending $3.6 million in 2025—the highest level in six years—to influence legislation that directly affects hospital margins and patient access.

The timing is critical. Federal policymakers are pursuing substantial reductions to Medicaid, the safety‑net program that underwrites care for millions of low‑income patients, and Congress has allowed generous ACA subsidies to lapse, eroding a reliable source of revenue for many health systems. These cuts translate into billions of dollars of lost reimbursements, pressuring hospitals to trim services, delay capital projects, or seek alternative financing. In this environment, a robust government‑relations strategy can mean the difference between maintaining solvency and confronting closures, especially for profit‑driven facilities that rely on volume and payer mix.

Schwartz’s blend of pharmaceutical policy expertise and deep familiarity with Capitol Hill dynamics positions her to navigate the increasingly politicized health‑care arena. At Merck, she cultivated relationships with key committees and helped shape drug‑pricing debates, experience that could prove valuable as FAH pushes back against Medicaid cuts and advocates for policies that preserve hospital revenue streams. Industry observers expect her leadership to sharpen FAH’s messaging around affordability, innovation, and access, potentially influencing upcoming budget negotiations and regulatory reforms that will shape the financial landscape of American hospitals for years to come.